2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Roswell Park Comprehensive Cancer Center surgeons will share their expertise during the 2025 annual meeting of the Society of Surgical Oncology.
Cancer Surgery | Image Credit:
© Katsyarina – stock.adobe.com
Cancer surgery leaders from Roswell Park Comprehensive Cancer Center will share their expertise with other cancer surgeons from around the world during the 2025 annual meeting of the Society of Surgical Oncology at the Tampa Convention Center in Tampa, Florida, March 27-29.
Moshim Kukar, MD, FACS, Chair of Surgical Oncology and Chief of Foregut and Endocrine Surgery at Roswell Park, will discuss how emerging biomarkers can inform the treatment of patients with gastroesophageal junction cancers. “Several agents, including chemotherapy, immunotherapy and targeted agents, can be combined in unique ways to achieve optimal results in both the curative and metastatic setting,” he notes.
He will chair Session 010, Biomarkers in Gastric and Esophageal Cancers, and present “Emerging Biomarkers of Treatment Response” as part of a symposium Thursday, March 27, from 8:20-9:50 a.m. EDT in Ballroom BC, with his presentation from 9:29-9:41 a.m.
Dr Kukar will also address general surgery residents who want to pursue SSO fellowships, during Session 052, Resident/Fellow Programming: Becoming a Surgical Oncologist: What Trainees Should Know for a Successful Match, Thursday, March 27, from 1:50-3:20 p.m. EDT in Room 124-125. His talk, “What It Takes to Successfully Match: Importance of the Interview, How to Structure Applicant Rank List,” takes place from 2:30-2:45 p.m. EDT.
Gary Mann, MD, FACS, Professor of Oncology in the Department of Surgical Oncology, will serve as moderator of Session 109, Great Debate: Less Is More, Or Is It? Right-Sizing of Thyroid Cancer Care, Friday, March 28, from 2:35-3:35 p.m. EDT in Ballroom D. The session will consider the extent of surgery in patients with low-risk, well-differentiated thyroid cancer as well as the timing and management of combination therapies in advanced, treatment-resistant or recurrent thyroid cancer, with an emphasis on common management challenges. Dr Mann will also serve on the Endocrine Disease Site Working Group that will convene during the meeting.
Faisal Jehan, MD, FICS, a Roswell Park Surgical Oncology Fellow, will give one poster and one video presentation, both recognized by the SSO as among the best in their categories:
The work of several Roswell Park fellows will be featured as e-posters:
This year’s SSO annual meeting includes Continuing the Conversation get-togethers that will give participants a chance to ask questions and share information with experts in an informal setting.
###
From the world’s first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide. Driven to eliminate cancer’s grip on humanity, the Roswell Park team of 4,000 makes compassionate, patient-centered cancer care and services accessible across New York State and beyond. Founded in 1898, Roswell Park was among the first three cancer centers nationwide to become a National Cancer Institute-designated comprehensive cancer center and is the only one to hold this designation in Upstate New York. To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit www.roswellpark.org, call 1-800-ROSWELL (1-800-767-9355) or email ASKRoswell@RoswellPark.org.
Related Content: